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Identity 
HGNC (Hugo): CLSPN 
Location: 1p34.3 
Note 
Claspin is a S-phase checkpoint factor that is activ ted 
in response to replication stress or other DNA damage 
induced by genotoxic agents. 
DNA/RNA 
Description 
The gene spans approximately 37 kb and contains 25 
exons. 
Transcription 
There are different transcripts variants, five of them 
encode for different isoforms. Two transcript variants 
encode for known proteins. The transcript variant 1 of 
4769 bp counts 25 exons. The transcript variant 2 of







The transcript variant 1 encodes for a protein of 1339 
aminoacids.  
The transcript variant 2 encodes for a protein of 1275 
amino acids. 
Expression 
Claspin peaks at S/G2 phase in response to DNA 
replication blocks and DNA damage. 
Localisation 
Claspin is located in the nucleus and it associates with 
Chk1 following replication fork stress or other types of 
DNA damage. 
Function 
Claspin is a S-phase checkpoint regulator required in 
response to DNA replication stress and to DNA 
damage induced by UV and irradiation (Chini and 
Chen, 2003; Sar et al., 2004; Freire et al., 2006; 
Tanaka, 2010).  
 
 
Figure 1. Schematic representation of the Claspin with the two transcript variants. The transcript variant 1 with 25 exons and the 
transcript variant 2 with 24 exons. The exons are indicated by boxes and introns by lines. 
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Figure 2. Claspin regulation during DNA damage checkpoint response pathway. Upon DNA damage, ATR activates Claspin, 
promoting the activation of the effector kinase Chk1. Once the damage is repaired, Plk1 binds and phosphorylates Claspin favoring its 
proteasomal degradation. 
 
Claspin is a mediator of ATR-Chk1 signaling cascade 
triggers for cell cycle checkpoint activation in DNA 
damage response.  
Claspin becomes phosphorylated and interacts with 
Chk1 promoting its activation by ATR-dependent 
phosphorylation (Chini and Chen, 2004; Kumagai and 
Dunphy, 2003; Clarke and Clarke, 2005).  
Claspin also interacts with the checkpoint proteins 
ATR and RAd9, and ATR regulates Claspin 
phosphorylation in presence of DNA damage induced 
by genotoxic stress including UV, IR and hydroxyurea, 
resulting in recruitment and phosphorylation of BRCA1 
(Jeong et al., 2003; Lin et al., 2004; Sørensen et al., 
2004). 
When DNA damage has been repaired, Claspin 
response is turned off by ubiquitin proteasome pathw y 
in order to inactivate checkpoint response and facilit te 
cells to enter the cell cycle.  
Therefore Claspin is phosphorylated by Plk1 kinase to 
permit its interaction with SCFβTrCP ubiquitin ligase that 
promotes its degradation (Mailand et al., 2006; Mamely 
et al., 2006; Peschiaroli et al., 2006). Claspin has also 
been found associated to replication forks in absence of 
DNA damage suggesting a function as a sensor 
required for replication fork stability (Sørensen et al., 
2004; Petermann et al., 2008; Scorah et al., 2009).  
Finally it has been observed a role of the Claspin in 
genome stability.  
Inhibition of the Claspin by RNA interference leads to 
both chromosome alterations and fragile site expression 
in human cells. Following aphidicolin treatment, 
Claspin increases due to its requirement to checkpoint 
activation, while its synthesis decrement after a 
prolonged aphidicolin treatment.  
It has been proposed that, following an extreme 
replication block, Claspin allows rare cells to escape 
checkpoint mechanisms and enter mitosis although 
their genome has not yet fully replicated (Focarelli t 
al., 2009). 
Homology 
This gene is present in S. cerevisiae as scMrc1; in S. 
pombe as spMrc1; in vertebrates as Claspin. 
Mutations 
Germinal 
- First study that reports the mutation screening of the 
CLSPN gene in familial breast cancer cases identifyi g 
different sequence changes (Erkko et al., 2008).  
Nevertheless no of these mutations is related to breast 
cancer susceptibility.  
- Sequence variants of Claspin have been identified n 
different human cancers. Eight nonsynonymous 
variants were found from the germline of two cancer-
prone individuals and five cancer cells lines of breast, 




Claspin expression levels increased in cancer cellsline  
and tumor specimens in a study performed in normal 
fibroblasts and various cancer cell lines, and from 
tumor and normal tissues of patients with primary 
epithelial carcinomas, in order to evaluate Claspin as a 
proliferation marker (Tsimaratou et al., 2007). 
Breast cancer 
Note 
Transcript levels of Claspin were highly detected in 
tumor breast cancer tissues in which estrogen receptor 
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Claspin expression is found significantly high in 
cervical cancer cell lines and the analysis of its 
expression could be clinically relevant in the diagnosis 
of Human Papillomavirus-related high grade lesions f 
uterine cervix (Benevolo et al., 2012). 
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